

Company Profile

Boehringer Ingelheim: Success through tradition and innovation

Boehringer Ingelheim is a research-driven pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. It is dedicated to the research, development, production and marketing of new medicines with high therapeutic benefit in the fields of Human Medicine and Veterinary Medicine. The Group consists of 146 affiliated companies and employs more than 47,700 people on all continents. In 2014, the company generated net sales amounting to some €13.3 billion. Boehringer Ingelheim was founded in 1885 by Albert Boehringer, and has been family-owned ever since. The shareholders and Board of Managing Directors alike are committed to remaining an independent, autonomous family company with a policy of organic growth. The traditional home and headquarters is in Ingelheim am Rhein.

The businesses of Boehringer Ingelheim

Generating 76 per cent share of total net sales, the business in prescription medicines is Boehringer Ingelheim's most important mainstay. The top-selling medicinal product with net sales of €3.2 billion was SPIRIVA® for the treatment of chronic obstructive pulmonary disease (COPD). The second biggest revenue contributor for Boehringer Ingelheim was the oral anticoagulant PRADAXA®. Net sales amounted to €1.2 billion, which corresponds to the previous year's level. The Boehringer Ingelheim Group is active in areas as diverse as diseases of the respiratory tract, the cardiovascular system and metabolic disorders, diseases of the central nervous system, oncology and immunology.

In the last financial year, Boehringer Ingelheim launched numerous innovative medications on the market, e.g. JARDIANCE® for the treatment of type 2 diabetes, OFEV® for the treatment of the rare disease idiopathic pulmonary fibrosis (IPF), and STRIVERDI® RESPIMAT® for patients with chronic obstructive pulmonary disease. At the beginning of 2015, Boehringer Ingelheim launched VARGATEF® for advanced lung cancer following chemotherapy.



Contact:

**Boehringer Ingelheim
Corporate Communications
Media + PR**

Heidrun Thoma
55216 Ingelheim/Germany
Phone: +49 6132 – 77 3966
Fax: +49 6132 – 77 6601
Email: [press@boehringer-
ingelheim.com](mailto:press@boehringer-ingelheim.com)



More information

www.boehringer-ingelheim.com



With Consumer Health Care (CHC) products, Boehringer Ingelheim last year generated 11 per cent of its total net sales. Top-selling products in this business field include the drugs BUSCOPAN®, DULCOLAX®, MUCOSOLVAN® and PHARMATON®. In addition to leading global brands, the company focuses on strong local products. Examples include the well-established medicine ZANTAC® in the USA and VAPRINO® and BOXAGRIPPAL® in Germany.

Boehringer Ingelheim in 2014 once again generated over €1 billion in net sales in veterinary medicines, which represents 8 per cent of total net sales. The strongest brand, with net sales of €260 million, was again the swine vaccine INGELVAC CircoFLEX®.

An important field for the company is the development and production of biopharmaceuticals. Boehringer Ingelheim leads in the biopharmaceutical development and production of medicinal products, which the company develops and produces using cell cultures or microorganisms at its facilities in Biberach (Germany), Vienna (Austria) and in Fremont (USA).

Global player with operations worldwide

In 2014, Boehringer Ingelheim generated its sales in the regions of North and South America (44 per cent), Europe (31 per cent) and Asia, Australia and Africa (25 per cent), with around 55 per cent of the consolidated sales attributable to the USA, Japan and Germany.

High research and development ratio

As a highly research-driven company, Boehringer Ingelheim's research and development (R&D) focus is on medicines and treatments. For this purpose, the company spent nearly €2.7 billion worldwide in 2014 – with R&D expenditure in the Prescription Medicines business area alone accounting for 23.1 per cent of the total sales generated in this business. The aim is to ensure continued growth of the pharmaceutical business with products resulting from in-house research and development. Boehringer Ingelheim operates a global research network with large production facilities in Germany (Biberach), the USA (Ridgefield) and Austria (Vienna).

Global research network for animal health

In order to react to emerging diseases quickly, wherever they appear, Boehringer Ingelheim has established a global research and development network in animal health. In 2012, the company opened a European research centre in Hanover (Germany) and an Asian research and development centre in Shanghai (China). In addition, for many years now Boehringer Ingelheim has operated other research centres for veterinary medicine in the USA, Mexico and Japan.

More information is available at www.boehringer-ingelheim.com and in the Annual Report 2014: annualreport.boehringer-ingelheim.com.

The publication is also available in the App Store and at Google Play as an App (for iPad and Android tablets).